Clinical study reports under the microscope

Nowhere in the pharmaceutical industry is the relationship between cost, price, and value better demonstrated than in the delivery of the clinical study report (CSR). Delivery of the CSR is often viewed simply as “dotting the i’s and crossing the t’s” at the end of the clinical trial process. Yet, once study participants have been thanked, samples analysed, and study documentation archived, the CSR remains one of the few enduring records of a study and may continue to be scrutinised throughout the lifetime of a medicinal product [1].

Will it reflect the care invested in conducting the study? Will it clearly represent the findings and communicate the value of the investigational medicinal product (IMP)? These questions highlight the importance of ensuring that the CSR is prepared by individuals with both scientific understanding and detailed knowledge of regulatory requirements.

The requirements for CSRs and the transparency of clinical trial data have evolved markedly over time, reflecting growing concerns regarding the ethical, scientific, and public-health implications of undisclosed research data [2][3][4][5].

Early regulations and ethical foundations

The history of clinical-trial transparency began in the mid-twentieth century, largely in response to ethical concerns surrounding human experimentation. Following the Nuremberg Trials, the Nuremberg Code established foundational principles governing research involving human participants [2].

Further ethical oversight was introduced through the Declaration of Helsinki in 1964. The Declaration emphasised that investigators have an ethical obligation to make research findings publicly available and that both positive and negative findings should be reported [3][4]. Although transparency requirements remained limited at that time, these principles laid the groundwork for later expectations regarding trial registration and public reporting of results.

Evolution of CSR requirements

As the pharmaceutical industry expanded during the latter half of the twentieth century, concerns emerged regarding selective reporting of clinical-trial outcomes. A major milestone was the publication of the International Conference on Harmonisation (ICH) E3 Guideline in 1995, which established a harmonised structure and content standard for clinical study reports submitted to regulatory authorities in Europe, Japan, and the United States [1].

Throughout the 1980s and 1990s, regulatory agencies increasingly required detailed study documentation to support marketing applications. However, these reports were generally treated as confidential regulatory documents and were not routinely accessible to the public.

During the 2000s, evidence accumulated that selective publication and outcome reporting could distort the medical evidence base. Analyses of antidepressant trials demonstrated that publication bias could substantially affect perceptions of efficacy and safety [5]. At Niche we worked on one of these high-profile cases for a blue chip pharma company that highlighted the potential for misunderstanding that can lead from not sharing study findings.

Key milestones in transparency

1. gov (2000): Established following the Food and Drug Administration Modernization Act of 1997, ClinicalTrials.gov created a publicly accessible registry for clinical studies [6].
2. FDA Amendments Act (FDAAA 801) (2007): Expanded registration and results-reporting obligations for applicable clinical trials, increasing public access to trial information [7].
3. European transparency initiatives (2014): Regulation (EU) No. 536/2014 and EMA Policy 0070 marked a significant shift towards proactive disclosure of clinical-trial information and selected clinical study reports [8][9].
4. AllTrials campaign (2013): The AllTrials initiative increased pressure on sponsors, regulators, researchers, and publishers to ensure that all clinical trials are registered and reported [10].

Current state of transparency (2017)

Today, transparency is widely recognised as essential for maintaining trust in medical research and protecting public health. There is growing support for ‘publication’ of clinical study reports and controlled access to participant data to permit independent verification of research findings [11][12].

At the same time, regulators, sponsors, and researchers continued to balance transparency against legitimate concerns regarding patient confidentiality, extent of informed consent, data anonymisation, and commercially confidential information [8][11].

Practical implications for CSR authors

To ensure prompt delivery of high-quality CSRs, authors must understand both regulatory requirements and the scientific context of the development programme. If you write the CSR yourself (assuming you have the know-how), you will avoid the cost of finding, employing and instructing a third party; however, the minimum price you pay will be loss of your valuable time. Your other responsibilities – such as programme management, site negotiations and addressing IMP issues – may affect your focus, preventing you from concentrating on the next task in hand.

Specialist medical writers and regulatory authors can often provide efficiencies through their familiarity with ICH E3 requirements, regulatory expectations and requirements, statistical reporting standards, and emerging transparency initiatives such as EMA Policy 0070 [1][8].

At Niche, we care about the quality of CSRs within the industry and have written more than 600 over the last 18 years. Through that experience we have identified recurring challenges and common errors that can delay submission or reduce document quality. Our introductory guide, An Insider’s Guide to Clinical Study Reports, provides practical insights to help sponsors avoid these common pitfalls [13]. Don't forget to sign up to receive future issues of Insider's Insights. We also welcome topic suggestions for future issues of the Insider's Insights.

References

1. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline E3: Structure and Content of Clinical Study Reports. Geneva: ICH; 1995.
2. United States Holocaust Memorial Museum. The Nuremberg Code. Washington (DC): USHMM; 1949.
3. World Medical Association. Human experimentation: code of ethics of the World Medical Association. Br Med J. 1964;2:177.
4. Carlson RV, Boyd KM, Webb DJ. The revision of the Declaration of Helsinki: past, present and future. Br J Clin Pharmacol. 2004;57(6):695-713.
5. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252-60.
6. Food and Drug Administration Modernization Act of 1997. Public Law 105-115.
7. Food and Drug Administration Amendments Act of 2007. Public Law 110-85, Section 801.
8. European Medicines Agency. Policy 0070 on publication of clinical data for medicinal products for human use. London: EMA; 2014.
9. European Parliament and Council. Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use. Off J Eur Union. 2014.
10. Goldacre B, Gray J. OpenTrials: towards a collaborative open database of all available information on all clinical trials.
11. Doshi P, Jefferson T, Del Mar C. The imperative to share clinical study reports: recommendations from the Tamiflu experience. PLoS Med. 2012;9(4):e1001201.
12. Institute of Medicine. Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk. Washington (DC): National Academies Press; 2015.
13. Niche Science & Technology Ltd. An Insider's Guide to Clinical Study Reports. Chester, UK: Niche Science & Technology Ltd; 2017.